Search Results - "Hänel, Gerulf"

Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells by Schmitt, Saskia, Tahk, Siret, Lohner, Alina, Hänel, Gerulf, Maiser, Andreas, Hauke, Martina, Patel, Lubna, Rothe, Maurine, Josenhans, Christine, Leonhardt, Heinrich, Griffioen, Marieke, Deiser, Katrin, Fenn, Nadja C, Hopfner, Karl-Peter, Subklewe, Marion

“…Conventional dendritic cell (DC) vaccine strategies, in which DCs are loaded with antigens , suffer biological issues such as impaired DC migration capacity…”
Get full text

Integrated multiomic approach for identification of novel immunotherapeutic targets in AML by Köhnke, Thomas, Liu, Xilong, Haubner, Sascha, Bücklein, Veit, Hänel, Gerulf, Krupka, Christina, Solis-Mezarino, Victor, Herzog, Franz, Subklewe, Marion

“…Immunotherapy of acute myeloid leukemia has experienced considerable advances, however novel target antigens continue to be sought after. To this end, unbiased…”
Get full text

T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals by Philipp, Nora, Kazerani, Maryam, Nicholls, Alyssa, Vick, Binje, Wulf, Jan, Straub, Tobias, Scheurer, Michaela, Muth, Amelie, Hänel, Gerulf, Nixdorf, Daniel, Sponheimer, Monika, Ohlmeyer, Malte, Lacher, Sonja M., Brauchle, Bettina, Marcinek, Anetta, Rohrbacher, Lisa, Leutbecher, Alexandra, Rejeski, Kai, Weigert, Oliver, von Bergwelt-Baildon, Michael, Theurich, Sebastian, Kischel, Roman, Jeremias, Irmela, Bücklein, Veit, Subklewe, Marion

“…T-cell–recruiting bispecific molecule therapy has yielded promising results in patients with hematologic malignancies; however, resistance and subsequent…”
Get full text

Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody by Augsberger, Christian, Hänel, Gerulf, Xu, Wei, Pulko, Vesna, Hanisch, Lydia Jasmin, Augustin, Angelique, Challier, John, Hunt, Katharina, Vick, Binje, Rovatti, Pier Eduardo, Krupka, Christina, Rothe, Maurine, Schönle, Anne, Sam, Johannes, Lezan, Emmanuelle, Ducret, Axel, Ortiz-Franyuti, Daniela, Walz, Antje-Christine, Benz, Jörg, Bujotzek, Alexander, Lichtenegger, Felix S., Gassner, Christian, Carpy, Alejandro, Lyamichev, Victor, Patel, Jigar, Konstandin, Nikola, Tunger, Antje, Schmitz, Marc, von Bergwelt-Baildon, Michael, Spiekermann, Karsten, Vago, Luca, Jeremias, Irmela, Marrer-Berger, Estelle, Umaña, Pablo, Klein, Christian, Subklewe, Marion

“…Antibody-based immunotherapy is a promising strategy for targeting chemoresistant leukemic cells. However, classical antibody-based approaches are restricted…”
Get full text

Accomplices in Cure: Blinatumomab + Dasatinib Reduces TCR Signaling and Effector Function Stronger Than Ponatinib and Ameliorates T-Cell Exhaustion by Philipp, Nora, Marcinek, Anetta, Hänel, Gerulf, Nixdorf, Daniel, Buecklein, Veit L., Subklewe, Marion

“…The tyrosine kinase inhibitors (TKIs) dasatinib (dasa) and ponatinib (pona) are being tested in clinical trials in philadelphia chromosome-positive (Ph +)…”
Get full text

Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens by Hänel, Gerulf, Angerer, Caroline, Petry, Katja, Lichtenegger, Felix S., Subklewe, Marion

“…Monocyte-derived Dendritic cells (DCs) have successfully been employed to induce immune responses against tumor-associated antigens in patients with various…”
Get full text

Beyond Mitigating Immune-Related Adverse Events: Glucocorticoids Ameliorate Bispecific Antibody-Mediated T-Cell Exhaustion I n Vitro by Muth, Amelie, Philipp, Nora, Marcinek, Anetta, Straub, Tobias, Winter, Lis, Hänel, Gerulf, Nixdorf, Daniel, Rohrbacher, Lisa, Buecklein, Veit L., Subklewe, Marion

“…Following the approval of blinatumomab in 2015 T-cell recruiting bispecific antibodies (BsAbs) became the established standard-of-care for relapsed or…”
Get full text

Fine Tuning Bispecific Activity in CLL: Harmonizing a CD19/20-T Cell Bispecific with a CD28 or 4-1BBL Costimulatory Bispecific by Rappa, Giulia Petra, Sponheimer, Monika, Hänel, Gerulf, Neumann, Anne-Sophie, Philipp, Nora, Korfi, Koorosh, Herter, Sylvia, Sam, Johannes, Schuler, Franz, Klein, Christian, Bacac, Marina, Umana, Pablo, Subklewe, Marion

“…Introduction: T cell bispecific antibodies (TCBs), such as blinatumomab, mosunetuzumab or glofitamab, redirect T cells toward cancer cells and rely on…”
Get full text

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study by Subklewe, Marion, Magno, Giulia, Gebhardt, Christina, Bücklein, Veit, Szelinski, Franziska, Arévalo, Héctor Julián Rincón, Hänel, Gerulf, Dörner, Thomas, Zugmaier, Gerhard, von Bergwelt-Baildon, Michael, Skapenko, Alla, Schulze-Koops, Hendrik

“…Systemic sclerosis, a severe inflammatory autoimmune disease, shares a common thread with cancer through the underlying mechanism of inflammation. This…”
Get full text

Two Players, One Goal: BiTE ® Vs CART Targeting FLT3 in AML by Rohrbacher, Lisa, Nixdorf, Daniel, Stadler, Helena, Brauchle, Bettina, Märkl, Florian, Philipp, Nora, Hänel, Gerulf, Marcinek, Anetta, Kazerani, Maryam, Emhardt, Alica Joana, Magno, Giulia, Goldstein, Rebecca L., Straub, Tobias, Kobold, Sebastian, Chapman-Arvedson, Tara L., Buecklein, Veit L., Subklewe, Marion

“…Translation of the success of bispecific T cell engagers (BiTE®) and CAR T cells from B-cell to myeloid malignancies has been challenging. Identifying suitable…”
Get full text

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells by Marcinek, Anetta, Brauchle, Bettina, Hänel, Gerulf, Lacher, Sonja M, Zieger, Nora, Kischel, Roman, von Bergwelt, Michael, Spiekermann, Karsten, Theurich, Sebastian, James, John R, Buecklein, Veit L, Subklewe, Marion

“…BiTE ® (Bispecific T-cell Engager) constructs represent a novel immunotherapeutic strategy that recruits T cells against cancer cells independent of their TCR…”
Get full text

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist by Hänel, Gerulf, Neumann, Anne-Sophie, Pulko, Vesna, Claus, Christina, Leutbecher, Alexandra, Marcinek, Anetta, Zieger, Nora, Buecklein, Veit L, Umana, Pablo, Klein, Christian, Subklewe, Marion

“…Bispecific antibodies represent a promising treatment option for acute myeloid leukemia (AML). We have recently described a novel T-cell bispecific antibody…”
Get full text

The Race Is on: BiTE Vs CART As FLT3-Directed Immunotherapies in AML by Rohrbacher, Lisa, Nixdorf, Daniel, Stadler, Helena, Brauchle, Bettina, Märkl, Florian, Phillip, Nora, Hänel, Gerulf, Marcinek, Anetta, Kazerani, Maryam, Goldstein, Rebecca, von Bergwelt, Michael, Kobold, Sebastian, Buecklein, Veit L, Chapman-Arvedson, Tara, Subklewe, Marion

Get full text

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment by Hänel, Gerulf, Schönle, Anne, Neumann, Anne-Sophie, Nixdorf, Daniel, Philipp, Nora, Sponheimer, Monika, Leutbecher, Alexandra, Emhardt, Alica-Joana, Magno, Giulia, Bücklein, Veit, Eckmann, Jan, Dunshee, Diana, Kramar, Vesna, Korfi, Koorosh, Colombetti, Sara, Umaña, Pablo, Klein, Christian, Subklewe, Marion

Get full text

CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells by Marcinek, Anetta, Brauchle, Bettina, Rohrbacher, Lisa, Hänel, Gerulf, Philipp, Nora, Märkl, Florian, Strzalkowski, Thaddäus, Lacher, Sonja M., Udiljak, Dragica, Spiekermann, Karsten, Theurich, Sebastian, Kobold, Sebastian, Kischel, Roman, James, John R., Bücklein, Veit L., Subklewe, Marion

“…Bispecific T-cell engager (BiTE ® ) molecules recruit T cells to cancer cells through CD3ε binding, independently of T-cell receptor (TCR) specificity. Whereas…”
Get full text

Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro by Zieger, Nora, Nicholls, Alyssa, Wulf, Jan, Hänel, Gerulf, Kazerani Pasikhani, Maryam, Buecklein, Veit, Brauchle, Bettina, Marcinek, Anetta, Nixdorf, Daniel, Rohrbacher, Lisa, Scheurer, Michaela, Kischel, Roman, Spiekermann, Karsten, Weigert, Oliver, Theurich, Sebastian, von Bergwelt, Michael, Subklewe, Marion

“…The bispecific T-cell engager (BiTE®) blinatumomab is approved for treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia and applied…”
Get full text

Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells by Marcinek, Anetta, Brauchle, Bettina, Rohrbacher, Lisa, Hänel, Gerulf, Philipp, Nora, Märkl, Florian, Strzalkowski, Thaddäus, Lacher, Sonja M., Udiljak, Dragica, Spiekermann, Karsten, Theurich, Sebastian, Kobold, Sebastian, Kischel, Roman, James, John R., Bücklein, Veit L., Subklewe, Marion

Get full text

Treatment-Free Intervals during CD19xCD3 BiTE ® Construct-Mediated T-Cell Stimulation Induce Functional Reinvigoration and Transcriptional Reprogramming of Exhausted T Cells by Zieger, Nora, Kazerani Pasikhani, Maryam, Straub, Tobias, Nicholls, Alyssa, Hänel, Gerulf, Wulf, Jan, Scheurer, Michaela, Nixdorf, Daniel, Sponheimer, Monika, Lacher, Sonja M, Brauchle, Bettina, Marcinek, Anetta, Rohrbacher, Lisa, Leutbecher, Alexandra, von Bergwelt, Michael, Spiekermann, Karsten, Weigert, Oliver, Theurich, Sebastian, Buecklein, Veit L, Kischel, Roman, Subklewe, Marion

“…Blinatumomab is a bispecific T-cell engager (BiTE ®) construct approved for treatment of relapsed/refractory (r/r) B-cell precursor acute lymphoblastic…”
Get full text

Targeting Intracellular WT1 in AML Utilizing a T Cell Bispecific Antibody Construct: Augmenting Efficacy through Combination with Lenalidomide by Klein, Christian, Augsberger, Christian, Xu, Wei, Heitmüller, Christina, Hanisch, Lydia, Sam, Johannes, Pulko, Vesna, Schönle, Anne, Challier, John, Carpy, Alejandro, Konstandin, Nikola, Rothe, Maurine, Hänel, Gerulf, Bücklein, Veit, Lichtenegger, Felix S., Tunger, Antje, Schmitz, Marc, von Bergwelt, Michael, Spiekermann, Karsten, Umana, Pablo, Subklewe, Marion

“…Antibody-based immunotherapy represents a promising strategy to target chemo-resistant leukemic cells. However, current antibody-based approaches are…”
Get full text

Abstract 894: The race is on: BiTE vs CART targeting FLT3 in AML by Rohrbacher, Lisa, Nixdorf, Daniel, Stadler, Helena, Brauchle, Bettina, Märkl, Florian, Philipp, Nora, Hänel, Gerulf, Marcinek, Anetta, Kazerani, Maryam, Goldstein, Rebecca L., von Bergwelt, Michael, Kobold, Sebastian, Bücklein, Veit L., Arvedson, Tara, Subklewe, Marion

“…Abstract Translation of the success of bispecific T cell engagers (BiTE®) and CAR T cells from B-cell to myeloid malignancies has been challenging. Identifying…”
Get full text